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Objective: We investigated the relationship between serum bilirubin levels and metabolic syndrome (MetS), and the longitudinal 
effects of baseline serum bilirubin concentrations on MetS in patients with schizophrenia spectrum disorders undergoing atypical 
antipsychotics. 
Methods: The sample of this study consisted of 131 patients with schizophrenia spectrum disorders. Waist circumference, blood 
pressure, and levels of triglycerides, high-density lipoprotein cholesterol, fasting glucose, and insulin were evaluated at baseline 
and at month six. Serum bilirubin levels were measured at baseline. Serum bilirubin levels of the patients with and without MetS 
criteria were compared. We also compared patients with high and low bilirubin levels (upper and lower 50th percentiles of serum 
bilirubin levels) in terms of MetS criteria, MetS frequency, and course of MetS.
Results: Serum direct bilirubin levels were more consistently related to MetS and MetS-related variables. The waist circumference 
and triglyceride criteria for MetS were significantly related to low serum direct bilirubin at baseline; waist circumference and 
fasting glucose criteria, and insulin resistance were associated with low serum direct bilirubin at follow-up. MetS diagnosis and 
the presence of the waist circumference criterion were more frequent at the baseline and the follow-up in low bilirubin group. 
At the end of the follow-up period, the rate of reverse MetS was significantly higher in the high bilirubin group.
Conclusion: Our results have suggested that serum direct bilirubin levels showed a more reliable and stable relationship with 
abdominal obesity for MetS components.in patients with schizophrenia spectrum disorders using antipsychotics. Further studies 
are required.
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INTRODUCTION
Metabolic syndrome (MetS) is a combination of meta-
bolic dysfunctions including abdominal or visceral 
adiposity, hypertension, glucose, and lipid abnormalities 
that increase the risk for cardiovascular disease and 
diabetes.1) MetS is a growing concern for routine psychi-
atric care when treating patients with schizophrenia be-
cause these metabolic abnormalities are regarded as a ma-
jor risk factor for cardiovascular diseases and mortality.2-4) 
Factors predisposing people with schizophrenia to MetS 
are complicated. Particularly second generation anti-
psychotics have been shown to greatly influence metabol-
ic risk factors leading to weight gain and impairing glu-
cose and lipid metabolism.5) The other risk factors among 
patients with schizophrenia are attributed to poor dietary 
habits, unhealthy lifestyle and physical inactivity, possi-
bly related to negative symptoms of schizophrenia.2) 
Weight gain and metabolic side effects of atypical anti-
psychotics also leads to non-adherence or rejection of 
treatment by the schizophrenia patients.6)
Bilirubin, the end product of heme metabolism, is an 
endogenous antioxidant with anti-inflammatory proper-
ties. High serum bilirubin concentrations are associated 
with increased total antioxidant capacity and offer pro-
tection against oxidative stress-induced diseases.7) MetS 
is characterized by enhanced low-grade systemic in-
flammation and oxidative stress. During the past few 
years, studies have shown that serum bilirubin levels are 
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inversely associated with MetS and systemic inflam-
mation in adults,8-11) children and adolescents.11) It have 
been reported that especially, abdominal obesity has been 
correlated with low serum bilirubin levels.11-13) Low se-
rum bilirubin has been proven to be associated with in-
creased carotid intima media thickness8,14) and peripheral 
arterial disease.15-17) In one study, low prevalence of ische-
mic heart disease in patients with Gilbert syndrome, a ge-
netic disorder causing mild to moderate elevations of un-
conjugated bilirubin, was detected.18) Bilirubin serum lev-
els are determined by genetic factors (intrinsic activity of 
enzymatic steps in bilirubin homeostasis), serum albumin 
concentration and its bilirubin-binding properties, and ex-
ternal factors such as dietary status, fasting, tobacco 
smoking, intake of drugs or plant products, living at alti-
tude, age, fitness level, and general health status.8) 
However, it has been reported that antipsychotic drugs do 
not cause significant changes in serum bilirubin levels.19)
To our knowledge, the relationship between the bilirubin 
levels and MetS has not been studied in patients with schiz-
ophrenia or schizoaffective disorder using antipsychotics. 
In this naturalistic follow-up study, the relationship be-
tween the bilirubin levels and MetS-associated parame-
ters, such as the frequency and course of MetS, was inves-
tigated in patients with schizophrenia spectrum disorders 
using antipsychotics. We also planned to investigate, if 
there is a relationship as we expected, the longitudinal ef-
fects of baseline serum bilirubin concentrations on in-
cident MetS during six-month follow-up period. We hope 
that our results will provide preliminary information on 
whether or not bilirubin levels are a potential predictor for 
MetS in patients with schizophrenia spectrum disorders 
using antipsychotics. In the follow-up period, we exam-
ined whether serum bilirubin levels were associated with 
the development or reversal of MetS in these patients. 
METHODS
Study Design and Population
The sample of the present study consisted of 151 patients 
who were diagnosed with schizophrenia or schizoaffective 
disorder according to the Diagnostic and Statistical Manual 
of Mental Disorders 4th edition (DSM-IV) criteria, aged 
18-65 years, and receiving atypical antipsychotics for at 
least 12 weeks. The study conducted on a subgroup of pa-
tients who enrolled in another prospective naturalistic 
study investigating the association between antipsychotic 
medication use and MetS in patients with schizophrenia 
spectrum disorders.20) This study supported by the 
Committee of Scientific Research Projects of Pamukkale 
University (Project Number: 2008TPF029). The patients 
were recruited from two treatment settings (Pamukkale 
University, Psychotic Disorder Outpatient Clinics and 
Denizli State Hospital, Turkey). Patients with the follow-
ing exclusion criteria were not recruited: psychotic dis-
orders or mood disorders due to a general medical con-
dition, dementia, substance abuse, or known hepatic dys-
function according to medical records.
The patients were evaluated at baseline and at month 
six. Antipsychotic medications and the severity of pos-
itive and negative symptoms were also recorded.21,22) At 
baseline visit, all patients received a full clinical examina-
tion, metabolic screening for MetS parameters and meas-
urement of serum bilirubin levels. Following the ex-
clusion of 8 patients with serum direct bilirubin values 
above the normal range (0.1-0.3 mg/dl) and 12 patients 
with indirect bilirubin levels above the normal range 
(0.2-0.7 mg/dl), the baseline sample included 131 patients 
(78 male, 53 female) and the follow-up sample included 
121 patients (72 male, 49 female). 
The Medical Ethics Committee of Pamukkale 
University approved the study protocol (protocol no: 
4837, 21.10.2008). Objectives and procedures of this 
study were explained to all patients; patients were in-
formed that their ongoing treatments would not be af-
fected by study procedures and written informed consent 
were obtained from all subjects prior to participation of 
the study.
All patients informed about their baseline measure-
ment, and relevant recommendations were given. For ex-
ample, patients with triglyceride (TG) and glucose levels 
meeting the MetS criteria were informed of the associated 
cardiovascular risk, advised to seek an endocrinology re-
ferral, and recommended to avoid high-calorie foods, to 
lose weight, to exercise, and to quit smoking. 
Anthropometric Measurements
Weight was measured with a spring balance that was 
kept on a firm horizontal surface. Subjects wore light 
clothing and stood upright without shoes, and weight was 
recorded to the nearest 0.5 kg. Height was measured with 
a tape to the nearest 0.1 cm. Subjects were requested to 
stand upright without shoes with their backs against the 
wall, heels together, and eyes directed forward. Waist cir-
cumference was measured in a standing position halfway 
between the costal edge and iliac crest. Body mass index 
(BMI) was calculated as the body weight in kilograms div-
ided by the height in meters squared.23) The blood pressure 
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Baseline MetS present 60 (45.8)
Free of MetS 71 (54.2)
Follow-up MetS present 61 (46.6)
Free of MetS at follow-up 60 (45.8)
Course of MetS
Continued MetS at both visits 46 (75.4)
Newly developed MetS at follow-up visit 15 (24.6)
Free of MetS at both visits 51 (85.0)
Reverse MetS at follow-up visit 9 (15.0)
Medications
Atypical antipsychotics 63 (48.1)
Atypical combinations 36 (27.5)




Values are presented as number (%).
MetS, metabolic syndrome.
measurements were obtained from the right arm with the 
participant in the sitting position using a mercury sphyg-
momanometer after 15 minutes of rest.
Serum Measurements
Overnight fasting blood samples were drawn and 
analyzed. Serum was immediately separated and stored at 
−20oC until subsequent analysis. Serum concentrations 
of direct (conjugated with glucuronic acid), indirect 
(unconjugated), and total bilirubin (includes both direct 
and indirect bilirubin), fasting glucose, TG, and high-den-
sity lipoprotein (HDL) cholesterol were measured on an 
AU 680 Chemistry System analyzer (Beckman Coulter, 
Nyon, Switzerland) using commercial kits. Serum insulin 
concentrations were analyzed on an ARCHITECT 
i2000SR analyzer (Abbott Diagnostics, Abbott Park, IL, 
USA) using commercial kits. The homeostasis model assess-
ment (HOMA) was used as a measure of insulin resistance 
(HOMA-IR). HOMA-IR was calculated using the formula: 
HOMA-IR=[glucose (mmol/L)×insulin (U/ml)/22.5] and 
insulin resistance was defined as HOMA-IR ＞2.7.19) All 
body and biochemical measurements were repeated at fol-
low-up visit.
Definition of Metabolic Syndrome
MetS was defined according to ATP III A (Adult 
Treatment Panel III A) criteria,20) which takes into account 
the following five components: Fasting triglycerides 
(FTG) ＞150 mg/dl; HDL ＜40 mg/dL (men) or ＜50 
mg/dl (women); blood pressure (systolic blood pres-
sure/diastolic blood pressure) ＞130/85 mmHg or on anti-
hypertensive medication; fasting glucose ＞100 mg/dl or 
on insulin or hypoglycemic medication; and waist circum-
ference ＞102 cm (men) or ＞88 cm (women). Patients 
having three or more of the criteria were identified as hav-
ing a MetS diagnosis. 
Statistical Analysis
Initially, in order to explore which bilirubin compo-
nents would be associated with MetS, the means of serum 
bilirubin levels (direct, indirect, and total) were compared 
between the patients with and without MetS criteria. As 
bilirubin values did not show a normal distribution, mean 
bilirubin levels of the groups were compared using the 
Mann-Whitney U test. 
These analyses revealed a consistent relationship be-
tween direct serum bilirubin levels and MetS criteria, 
therefore we performed subsequent analyses based on a 
recent report on the lower risk of MetS in patients with se-
rum bilirubin levels at upper percentiles.10) The patients 
within the lower 50th percentile of serum direct bilirubin 
levels (low bilirubin group) were compared to those with-
in the upper 50th percentile (high bilirubin group) in terms 
of MetS criteria using the chi-square test. 
The stability of the relationship between serum bilir-
ubin levels and MetS was tested by examining the rela-
tionship between the baseline serum bilirubin levels and 
MetS associated parameters at follow-up.
The relationship between bilirubin levels and MetS cri-
teria was also investigated using partial correlation analy-
sis while controlling for the effect of age. p＜0.05 was ac-
cepted to be statistically significant. Statistical analyses 
were performed using SPSS software 17.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Bilirubin levels were measured in 151 patients at the be-
ginning of study. For baseline sample, average age, mean 
duration of disease, and mean number of hospitalizations 
were determined to be 38.98±12.21 years, 13.32±9.74 
years, and 2.84±3.57 respectively. Frequency of MetS di-
agnosis was 45.8% at the baseline and 46.6% at follow-up 
(Table 1). Frequency of MetS diagnosis was not sig-
nificantly different between men and women in either 
visit. Criteria for MetS diagnosis were met by 47.2% of 
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MetS present 60 0.075±0.066 0.264±0.127 0.347±0.142
Free of MetS 71 0.121±0.093 0.002 0.290±0.178 0.193 0.421±0.203 0.011
Individual MetS criteria
BP criterion present 35 0.105±0.081 0,267± 0.128 0.369±0.166
Free of BP criterion 96 0.103±0.087 0.958 0.292±0.166 0.339 0.397±0.198 0.429
FG criterion present 46 0.091±0.082 0.267±0.137 0.358±0.154
Free of FG criterion 85 0.102±0.083 0.341 0.291±0.165 0.399 0.397±0.201 0.249
WC criterion present  80 0.085±0.075 0.248±0.141 0.333±0.161
Free of WC criterion 51 0.126±0.090 0.006 0.337±0.163 0.001 0.464±0.198 0.000
HDL criterion present 96 0.095±0.082 0.281±0.144 0.377±0.178
Free of HDL criterion 35 0.115±0.087 0.193 0.287±0.186 0.843 0.4034±0.212 0.488
TG criterion present 57 0.076±0.068 0.277±0.116 0.353±0.136
Free of TG criterion 74 0.120±0.090 0.003 0.287±0.181 0.707 0.408±0.216 0.081
Insulin resistance present 33 0.087±0.083 0.276±0.151 0.363±0.165
No insulin resistance 98 0.105±0.084 0.176 0.285±0.158 0.934 0.391±0.194 0.683
Follow-up visit
MetS present 61 0.077±0.061 0.289±0.141 0.366±0.1622
Free of MetS 60 0.112±0.091 0.016 0.286±0.161 0.930 0.399±0.197 0.314
Individual MetS criteria
BP criterion present 45 0.092±0.079 0.264±0.142 0.356±0.171
Free of BP criterion 76 0.097±0.076 0.627 0.304±0.151 0.220 0.399±0.185 0.206
FG criterion present 53 0.078±0.067 0.290±0.132 0.369±0.162
Free of FG criterion 68 0.107±0.085 0.039 0.285±0.164 0.846 0.394±0.194 0.459
WC criterion present 66 0.084±0.076 0.281±0.16 0.366±0.180
Free of WC criterion 55 0.106±0.081 0.124 0.295±0.13 0.629 0.403±0.181 0.266
HDL criterion present 87 0.090±0.075 0.286±0.140 0.378±0.169
Free of HDL criterion 34 0.105±0.088 0.377 0.291±0.176 0.876 0.396±0.208 0.621
TG criterion present 55 0.084±0.072 0.303±0.125 0.388±0.159
Free of TG criterion 66 0.103±0.084 0.063 0.274±0.169 0.293 0.379±0.198 0.78
Insulin resistance present 49 0.072±0.068 0.286±0.142 0.365±0.167
No insulin resistance 72 0.105±0.084 0.055 0.288±0.157 0.824 0.395±0.189 0.506
Course of MetS
MetS at both visits 46 0.063±0.054 0.276±0.126 0.339±0.146
Reverse MetS at follow-up 9 0.115±0.088 0.022 0.264±0.111 0,795 0.380±0.175 0.163
Free of MetS at both visits 51 0.123±0.127 0.317±0.177 0.439±0.046
Newly developed MetS at follow-up 16 0.111±0,092 0.621 0.290±0.169 0.611 0.403±0.028 0.530
Values are presented as mean±standard deviation.
MetS, metabolic syndrome; BP, blood pressure; FG, fasting glucose; WC, waist circumference; HDL, high density lipoprotein; TG, triglyceride.
By Mann-Whitney U test. 
women and 49.9% of men at baseline and 49.9% of wom-
en and 52.8% of men at follow-up (p＞0.05). At the base-
line evaluation, average age of the patients with MetS 
(43.95±11.01 years) was significantly higher than those 
without MetS (34.78±11.65 years) (p=0.000).
Most of the patients with MetS (75.4%) at follow-up 
visit were patients who met criteria for MetS in both visits 
and 24.6% were patients who developed MetS within the 
six months between visits. Most of the patients (85%) 
without MetS at follow-up visit were free of MetS at base-
line and 15% were reverse MetS patients. Most of our pa-
tients were treated with single or combined atypical anti-
psychotics (Table 1).
The Relationship between Serum Bilirubin Levels and 
MetS Diagnosis, and Its Stability
The mean serum direct bilirubin and total bilirubin lev-
els of the patients with MetS diagnosis were significantly 
lower than those free of MetS. This relationship was also 
evident at follow-up. Regarding the course of MetS, the 
patients who met the diagnosis of MetS in both visits had 
significantly lower direct bilirubin levels compared to pa-
tients with reversed MetS diagnosis at the end of the fol-
low-up period (Table 2). 
Serum direct bilirubin levels were also significantly 
lower in patients who met the MetS criterion for waist cir-
cumference at baseline as compared to patients who were 
free of this criterion. The presence of TG level criteria for 
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Table 3. Relationship of serum bilirubin levels according to the number of MetS components
Number of MetS criteria Number (%) Direct bilirubin level (mg/dl) Indirect bilirubin levels (mg/dl)
Baseline  
None 10 (7.6) 0.140±0.078 0.395±0.210
Having 1 criteria for MetS 31 (23.7) 0.113±0.087 0.292±0.185
Having 2 criteria for MetS 29 (22.1) 0.117±0.099 0.273±0.147
Having 3 criteria for MetS 29 (22.1) 0.089±0.065 0.272±0.135
Having 4 criteria for MetS 24 (18.3) 0.072±0.082 0.252±0.128
Having 5 criteria for MetS 8 (6.1) 0.075±0.052 0.266±0.104
Follow-up
None 11 (8.4) 0.105±0.093 0.267±0.148
Having 1 criteria for MetS 27 (20.6) 0.118±0.087 0.307±0.187
Having 2 criteria for MetS 22 (16.8) 0.103±0.099 0.270±0.133
Having 3 criteria for MetS 26 (19.8) 0.089±0.061 0.293±0.149
Having 4 criteria for MetS 25 (19.1) 0.084±0.065 0.304±0.143
Having 5 criteria for MetS 10 (7.6) 0.040±0.023 0.240±0.110
Values are presented as number (%) or mean±standard deviation.
MetS, metabolic syndrome.
MetS was significantly related to low serum direct bilir-
ubin levels at the baseline, but this relationship was not 
evident at follow-up. Interestingly, at the follow-up visit, 
low serum direct bilirubin levels showed a significant re-
lationship with the presence of fasting glucose level cri-
teria and were associated with insulin resistance, nearly to 
a significance level, despite no association at baseline 
(Table 2).
The patients with MetS diagnosis and the patients who 
met the waist circumference criterion had lower total bilir-
ubin levels compared to their counterparts. Indirect bilir-
ubin levels showed only significant association with base-
line waist circumference (Table 2). Serum total and in-
direct bilirubin did not show any significant association 
with the course of MetS. 
Mean serum direct and indirect bilirubin levels of the 
patient based on the number of present MetS criteria are 
provided in Table 3. Linear regression analysis showed a 
significant relationship between direct bilirubin levels and 
the number of met criteria at baseline (B=−3,876, ad-
justed R square=0.048, p=0.007) and at follow-up evalua-
tion (B=−3,734, adjusted R square=0.033, p=0.026). 
This relationship was not observed for indirect bilirubin 
levels (p＞0.05). 
Low versus High Bilirubin Groups 
These initial analyses revealed a consistent relationship 
between direct serum bilirubin levels and MetS, therefore 
we performed subsequent analyses based on a recent re-
port on the lower risk of MetS in patients with serum bilir-
ubin levels at upper percentiles.10) We divided the patient 
into two groups: The patients within the first 50th percen-
tile of serum direct bilirubin levels (low bilirubin group) 
and within the second 50th percentile (high bilirubin 
group). 
MetS diagnosis was significantly more frequent in the 
low bilirubin group compared to the high bilirubin group 
at baseline (respectively 58.8% vs. 32.3%) and follow-up 
(respectively 60.3 % vs. 37.7 %) (Table 4). In the high bi-
lirubin group, significantly more patients were free of the 
waist circumference criterion compared to the low bilir-
ubin group at baseline (53.2% vs. 26.1%) and follow-up 
(56.6% vs. 36.8%). In this group, significantly more pa-
tients were also free of TG level criteria at baseline and 
fasting glucose level criteria at follow-up (Table 4). 
However, more patients were free of blood pressure cri-
teria at baseline and TG level criteria at follow-up in the 
high bilirubin group, but the differences between groups 
did not prove significant. Low and high bilirubin groups 
were not different in respect to the presence of insulin re-
sistance at baseline or follow-up.
Regarding the course of MetS at the end of six months, 
MetS diagnosis was still present in 90% of the patients 
with low bilirubin and 66.7% of patients in the high bilir-
ubin group. The ratio of patients with reverse MetS was 
significantly higher in the high bilirubin group compared 
to the low bilirubin group (33.3 % vs. 10%) (Table 4).
Correlations between Bilirubin Levels and MetS 
Associated Parameters
Consistent with the above findings, direct bilirubin lev-
els showed a significant negative correlation with waist 
circumference (r=−0.178, p=0.042 for both visits) and 
TG levels (r=−0.243, p=0.005 for baseline; r=−0.185, 
p=0.042 for follow-up). In addition, fasting blood glucose 
at follow-up showed a significant negative correlation 
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Table 4. Comparison of MetS and its individual criteria in low and high bilirubin groups at baseline and follow-up visit
Variable
Low bilirubin group 
(0.01-0.09 mg/dl)
High bilirubin group 
(0.10-0.30 mg/dl)
2 p value
Female 29 (42.0) 24 (38.7) 0.149 0.699
Male 40 (58.0) 38 (61.3)
Baseline MetS present 40 (58.0) 20 (32.3) 8.698 0.003
Free of MetS 29 (42.0) 42 (67.7)
Follow-up MetS present 41 (60.3) 20 (37.7) 6.063 0.014
Free of MetS 27 (39.7) 33 (62.3)
Baseline individual MetS criteria
Blood pressure
Present (n=35) 20 (44.1) 15 (28.3)
Free of (n=76) 38 (55.9) 38 (71.7) 3.191 0.074
Fasting glucose
Present (n=46) 28 (40.6) 18 (29.0) 1.911 0.167
Free of (n=85) 41 (59.4) 44 (71.0)
Waist circumference
Present (n=60) 51 (73.9) 29 (46.8) 10.117 0.001
Free of (n=51) 18 (26.1) 33 (53.2)
HDL levels
Present (n=96) 54 (78.3) 42 (67.7) 1.846 0.174
Free of (n=35) 15 (21.7) 20 (32.3)
Triglyceride levels
Present (n=57) 37 (51.5) 20 (37.7) 6.065 0.014
Free of (n=74) 32 (48.5) 42 (62.3)
Insulin resistance present (n=33) 21 (30.4) 12 (19.4) 2.127 0.145
No insulin resistance (n=98) 48 (69.6) 50 (80.6)
Follow-up individual MetS criteria
Blood pressure
Present (n=45) 30 (44.1) 15 (28.3) 3.190 0.074
Free of (n=76) 38 (55.9) 38 (71.7)
Fasting glucose
Present (n=53) 36 (52.9) 17 (32.1) 5.268 0.022
Free of (n=68) 32 (47.1) 36 (67.9)
Waist circumference
Present (n=66) 43 (63.2) 23 (43.4) 4.728 0.030
Free of (n=55) 25 (36.8) 30 (56.6)
HDL levels
Present (n=87) 51 (75.0) 36 (67.9) 0.738 0.390
Free of (n=34) 17 (25.0) 17 (32.1)
Triglyceride levels
Present (n=55) 35 (51.5) 20 (37.7) 2.266 0.093
Free of (n=66) 33 (48.5) 33 (62.3)
Insulin resistance present (n=49) 32 (47.1) 17 (32.1) 2.775 0.096
No insulin resistance (n=72) 36 (52.9) 36 (67.9)
Course of MetS
Continued MetS at both visits 36 (90.0) 10 (66.7) 4.340 0.037
Reverse MetS at follow-up visit 4 (10.0) 5 (33.3)
Free of MetS at both visits 23 (82.1) 28 (71.8) 0.960 0.327
Newly developed MetS at follow-up visit 5 (17.9) 10 (28.2)
Values are presented as number (%).
MetS, metabolic syndrome; HDL, high-density lipoprotein. 
By Pearson chi-square analysis.
with direct bilirubin levels (r=−0,222, p=0.014). 
Direct bilirubin levels did not show any significant cor-
relations with weight, BMI, HOMA, or fasting insulin 
levels. No significant correlation was found between in-
direct bilirubin levels and MetS parameters. Serum bilir-
ubin levels of smoking and non-smoking patients were not 
significantly different. 
DISCUSSION
Our study has found that direct bilirubin levels are asso-
ciated with the diagnosis and the course of MetS in patient 
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with schizophrenia spectrum disorders. Our results are 
similar to those of previous studies conducted in general 
populations, overweight individuals, and patients with 
cardiovascular disorder.9-17,24-29) In our study, the main 
MetS parameters associated with bilirubin levels were 
waist circumference and TG levels. Low serum direct bi-
lirubin levels were found to be associated with baseline 
and follow-up MetS diagnosis, with the presence of waist 
circumference and TG level criteria at baseline, and with 
fasting glucose level criteria at follow-up. Serum indirect 
bilirubin levels only showed significant association with 
the presence of waist circumference criteria at baseline. 
Recently, it was demonstrated that bilirubin is a potent en-
dogenous antioxidant and also plays a protective role in 
several stages of atherosclerotic inflammation. In cases of 
obesity and MetS where oxidative stress is increased, con-
sumption of bilirubin increases, leading to a reduction in 
serum bilirubin levels which results in an increased risk of 
cardiovascular diseases by causing endothelial dysfunc-
tion.7,8,26,30)
Relationship between Direct and Total Bilirubin and 
Metabolic Syndrome
The relationship between serum direct bilirubin levels 
and MetS, as demonstrated in our study, has also been 
shown in many previous studies.8-13) Jo et al.10) have re-
ported the bilirubin subtype that showed the most con-
sistent relationship with MetS diagnosis as direct bilirubin 
in a sample of 5,321 patients. The relationship between di-
rect bilirubin and MetS diagnosis observed in both visits 
in our study also supports this finding. We also observed 
that the more lower direct bilirubin levels were related to 
the more number of criteria for MetS were present as re-
ported by Jenko-Pražnikar et al.26) Recent studies suggest 
that the risk of MetS is increased two- to five-fold in pa-
tients with serum direct bilirubin levels that fall within the 
lower interquartile percentile (0th-75th percentile) as 
compared to patients within the uppermost percentile 
(75th-100th percentile) and an increase of 1 standard devi-
ation in total bilirubin level reduces the risk of MetS by 
17%. Likewise, our study revealed that MetS diagnosis 
was significantly lower in the high bilirubin group. In 
these patients, reversed MetS rate was also found to be sig-
nificantly higher than the low bilirubin group. In con-
clusion, these findings, consistent with the literature, sug-
gest that high direct serum bilirubin levels may be asso-
ciated with a lower risk of MetS in schizophrenia patients 
undergoing antipsychotic treatment.
Relationship between Serum Bilirubin and MetS 
Parameters
Abdominal obesity
While waist circumference was significantly associated 
with all bilirubin forms at baseline, it was associated with 
only direct bilirubin levels at follow-up. Direct bilirubin 
levels were significantly lower in patients who met the 
MetS criterion for waist circumference at baseline and fol-
low-up evaluation as compared to patients who did not 
meet this criterion. In addition, the presence of waist cir-
cumference criteria was significantly higher in the low bi-
lirubin group as compared to the high bilirubin group at 
the baseline and follow-up visits. Correlation analyses al-
so showed a significant negative correlation between 
waist circumference and direct bilirubin levels. Consistent 
with our results, the literature reports that abdominal obe-
sity alone has been correlated with low serum bilirubin 
levels.8,11-13,24,25) Choi et al.8) have reported an inverse rela-
tionship between the high levels of bilirubin and abdomi-
nal obesity. Serum bilirubin was found to be inversely as-
sociated with the amount of visceral adipose tissue in 
2,450 subjects examined in a Swedish Obese Subjects trial 
and this finding was considered a reflection of MetS in 
obese individuals.31) Kwon et al.13) have examined the bi-
lirubin levels in women by dividing them into four catego-
ries by interquartile ranges and reported a significant rela-
tionship between high levels of bilirubin and lower waist 
circumference. Jenko-Pražnikar et al.26) have also re-
ported serum bilirubin levels were negatively associated 
with abdominal obesity in overweight asymptomatic mid-
dle-aged individuals. Distinct from above mentioned 
studies, Andersson et al.32) have reported in the results of 
their study that weight loss causes an increase in serum bi-
lirubin concentration. Abovementioned studies and our 
study have pointed out the relationship between serum bi-
lirubin levels and obesity. 
Dyslipidemia and abnormal glucose metabolism
In our study, TG levels were associated with lower di-
rect bilirubin concentrations. However, baseline and fol-
low-up data were partially inconcistent. Correlation anal-
yses showed that the negative relationship was maintained 
between direct bilirubin and TG levels at both baseline 
and follow-up. However, direct bilirubin levels were sig-
nificantly lower in patients who met the MetS criterion for 
TG levels compared to patients who didn't meet this crite-
rion at baseline; the differences between these two groups 
was not present at follow-up. Similarly, the presence of the 
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MetS criterion for TG levels at baseline was significantly 
lower in the high bilirubin group, but this relationship was 
less apperent at follow-up. The relationship between bilir-
ubin and lipid profile was first reported by Breimer et al.28) 
in a large cohort of middle-aged, British men. This study 
indicated lower concentrations of TG and higher concen-
trations of HDL in individuals with higher bilirubin 
concentrations. A number of subsequent studies described 
negative relationships between bilirubin and TG lev-
els8,24,26,29) as well as bilirubin showed a positive associa-
tion with HDL concentrations.8,13,24,27,30) Chang et al.24) re-
ported that serum direct bilirubin levels were inversely as-
sociated with total cholesterol, low-density lipoprotein 
(LDL) cholesterol, and TG, and positively associated with 
HDL cholesterol levels. Yoshino et al.30) reported a pos-
itive correlation between total bilirubin and HDL levels in 
an overweight group. Onat et al.27) reported a significant 
linear relationship between bilirubin levels and HDL cho-
lesterol in men. Jenko-Pražnikar et al.26) also reported that 
serum bilirubin levels were negatively associated with 
FTG, total cholesterol, and LDL cholesterol in overweight 
individuals.
In our study, lipids other than TG showed no relation-
ship with bilirubin levels, which may be due to several 
reasons. Most of the previously published studies were 
conducted with large sample sizes, whereas the relatively 
small sample size in this study may limit the validity of our 
results. Additionally, atypical antipsychotics have been 
shown to have negative effects on lipid profile (levels of 
TG, total cholesterol, HDL cholesterol, etc.).6,33) Most of 
our patients were treated with atypical antipsychotics, 
which may have acted as a confounding factor on our 
results. Some studies also suggest that the relationship be-
tween bilirubin levels and serum lipids may vary based on 
sex.26,27) Further well-controlled studies on the relation-
ship between serum lipid profile and bilirubin levels in pa-
tients undergoing antipsychotic treatment, controlling for 
the effect of confounding factors, may provide more in-
formation about this issue. Nevertheless, our findings are 
consistent with the literature in that there is a relationship 
between low levels of bilirubin and high levels of tri-
acylglycerol, which is the most remarkable result of most 
studies examining this matter in healthy subjects.34) 
In our study, serum direct bilirubin levels were sig-
nificantly lower in patients who met the MetS criterion for 
fasting glucose levels only at follow-up visit as compared 
to patients who were free of this criterion. At follow-up, 
low serum direct bilirubin levels tended to accompany the 
presence of insulin resistance. There were no relationships 
observed between the bilirubin levels and fasting insulin 
levels or HOMA-IR values. Although our results suggest 
a limited relationship between direct bilirubin levels and 
glucose metabolism in patients using antipsychotics, the 
results do not allow for a conclusion to be made on this 
matter. Previous studies have reported that serum total bi-
lirubin concentrations were inversely associated with hy-
perinsulinemia, insulin resistance, and systemic inflam-
mation.12,26) The absence of a consistent relationship be-
tween bilirubin levels and glucose metabolism in our 
study, distinct from previous studies, may be attributed to 
characteristics of our patient group, such as the limited 
sample size and use of antipsychotics. A study conducted 
in a general population with 1,052 Turkish adult patients 
showed that total bilirubin levels are associated with in-
sulin resistance but not associated with abdominal 
obesity.27) This, as in our study, suggests that the relation-
ship of bilirubin levels with MetS and its parameters in pa-
tients using antipsychotics, may have different character-
istics than those observed in the general population. 
However, more studies are required on this issue. 
Oxidative stress is believed to play a pathophysio-
logical role in schizophrenia. Studies addressing the rela-
tionship between bilirubin levels and schizophrenia or 
psychosis report conflicting results.35,36) Studies also sug-
gest that oxidative stress is involved in the pathogenesis of 
MetS and as a natural antioxidant, bilirubin may play a 
protective role against oxidative stress and atherosclerotic 
processes in healthy individuals.7,8,30) Our results suggest 
that bilirubin may also involve in MetS accompanied to 
schizophrenia. However, as our research is the first study 
on this issue, these conclusions must be supported with fu-
ture studies.
The most important result of this study may be summar-
ized as follows: Firstly, direct bilirubin levels are asso-
ciated with several MetS associated parameters, including 
MetS diagnosis, abdominal obesity, and TG levels. 
Secondly, high levels of direct serum bilirubin were asso-
ciated with a lower risk of MetS in patients with schizo-
phrenia spectrum disorders using antipsychotics. Our 
study is the first to investigate the association of bilirubin 
with MetS and its parameters in patients with schizo-
phrenia spectrum disorders. The key strength of our study 
is that it covers the longitudinal effects of baseline serum 
bilirubin concentrations on incident MetS for six-month 
follow-up period. The relationships of MetS diagnosis and 
abdominal obesity with direct bilirubin levels remained 
stable during the six-month follow-up period. This sug-
gests that the direct bilirubin value measured at any given 
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time may be a useful predictor for abdominal obesity. 
Jenko-Pražnikar et al.26) also reported that a low level of 
bilirubin in non-symptomatic individuals may be an early 
biomarker of MetS. We could not find a study that pro-
spectively investigates the stability of the relationship be-
tween bilirubin levels and MetS parameters in the litera-
ture. Most of the atypical antipsychotics currently used in 
the treatment of schizophrenia increase the risk of MetS 
and worsen metabolic parameters, beginning soon after 
treatment initiation.6,33) A factor with a stable relationship 
with MetS over time, may be used as a predictor to reduce 
the risk of MetS. High levels of direct bilirubin in patients 
with schizophrenia spectrum disorders may be a cost-ef-
fective indicator to demonstrate lower risk of MetS. In ad-
dition, antipsychotics that have strong metabolic side ef-
fects may be avoided in patients with low serum direct bi-
lirubin levels, as to reduce the interference when evaluat-
ing for the risk of MetS. However long-term studies with 
a larger sample are required on this matter. Important limi-
tations of our study include our limited sample size and the 
absence of a control group. Another limitation of our 
study is the widespread use of antipsychotics in our patient 
population. Although it was reported that antipsychotics 
do not affect the levels of serum bilirubin,19) we can not ex-
clude the possible confounding effect of antipsychotics. 
An investigation on the effects of antipsychotics on MetS 
and bilirubin levels starting from the initiation of therapy 
would better clarify this matter.
Our study suggests that the limited, yet stable relation-
ship of bilirubin with abdominal obesity, the key charac-
teristic of MetS, may be worth further investigating.
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